Saphnelo
Saphnelo ingredients
| Active ingredient | Strength |
|---|---|
| Anifrolumab | 120 mg/.8mL, 300 mg/2mL |
What Saphnelo is used for
The FDA lists the approved uses on the official label (below). In the EU, anifrolumab is approved as Saphnelo for:
Saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE), despite standard therapy.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Saphnelo
- Generic name
- Anifrolumab-fnia
- Made by
- AstraZeneca Pharmaceuticals LP
- Forms
- Injection, Solution
- Given
- Intravenous, Subcutaneous
- Drug class
- Type I Interferon Receptor Antagonist
- FDA approval
- Biologic licence (BLA) BLA761451
- On the US market since
- 2021
Official information
- MedlinePlus drug information (search for Anifrolumab-fnia)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Saphnelo?
Saphnelo (Anifrolumab-fnia) is a specialist medicine made by AstraZeneca Pharmaceuticals LP, approved by the US FDA.
What are the ingredients of Saphnelo?
Saphnelo contains Anifrolumab (120 mg/.8mL, 300 mg/2mL).
Is Saphnelo approved in Europe?
The same active substance is approved in the EU as Saphnelo.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA